Its blockbuster product , the AVONEX , resulted in average 1 billion of sales /year since 2001 . Its newcomer , the AMEVIVE is also displaying significant importance as drugs for treating worldwide patients suffering from autoimmune diseases . The corporation owns superior biological products that allow it to make broad plans for future productions . Its product line is trusted by medical facilities due to its satisfactory prior performance presented by the AVONEX . Nevertheless , sales of the drug seemed to lack growth in 2002 . There...











SUBJECTS

